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doi:10.1016/j.kjms.2012.04.030Abstract This is a case study of a 61-year-old male who presented with difficult defecation
for 1 month. A circumferential submucosal rectal tumor was noted on a digital rectal exami-
nation and colonoscopy. Laboratory examination revealed high serum levels of carcinoembryo-
nic antigen (CEA; 43.75 ng/mL) and carbohydrate antigen 19-9 (CA19-9; 11,790 U/mL). In
addition, tumor biopsies revealed a poorly differentiated adenocarcinoma of the rectum with
intact mucosa. The patient had history of advanced stage-T2 urothelial cell carcinoma of
bladder, which had been downstaged to T0 by neoadjuvant chemotherapy followed by radical
cystectomy 1 year prior. After investigating the initial bladder tumor specimens, a small
portion of the tumor with high CEA expression comparable to the submucosal rectal tumor
was found. The size of the tumor was reduced and the levels of the tumor markers decreased
after administering FOLFIRI chemotherapy targeted at the adenocarcinoma. Although neoad-
juvant chemotherapy may have a selective pressure to eliminate most urothelial cell carci-
noma, physicians should be aware that it can lead to rectal metastasis via CEA-producing
components.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
The majority of primary carcinomas of the urinary bladder
are urothelial cell carcinomas. Here, we report a patientrology, Department of Surgery, T
.com.tw (T.-L. Cha).
vier Taiwan LLC. All rights reservwho had a history of urothelial cell carcinoma of the
bladder after neoadjuvant chemotherapy followed by
radical cystectomy who subsequently developed poorly
differentiated rectal adenocarcinoma with elevated plasmari-Service General Hospital, Number 325, Cheng-Kung Road, Sec. 2,
ed.
Chemotherapeutic pressure in bladder cancer 625CEA (43.75 ng/mL) and CA19-9 (11,790 unit/mL) levels.
These conditions might have risen from a CEA-producing
component in a previous tumor and be related to intra-
tumoral heterogeneity. The different tumor components
may have various sensitivity levels to chemotherapy,
resulting in remote metastases even though the primary
tumor was eliminated.
Case report
A 61-year-old man presented with 3 weeks of abdominal
distension in June 2009. In April 2008, the patient was
diagnosed with a urothelial cell carcinoma that was situ-
ated on the left posterior wall of the urinary bladder; this
carcinoma had been treated by transurethral resection of
tumor. The surgical specimen was diagnosed as a high-
grade urothelial cell carcinoma of bladder (Fig. 1) with
muscle invasion (T2N0M0) and was immunohistochemically
positive for cytokeratin 7 and negative for cytokeratin 20
and prostate-specific antigen (PSA). Six cycles of neo-
adjuvant chemotherapy (paclitaxel, gemcitabine, and car-
boplatin) were administered. In August 2008, the patient
received a radical cystectomy, but the ileal conduit showed
no residual evidence of the tumor on the pathological
report. Another four cycles of adjuvant chemotherapy were
administered after the operation. The patient was then
transferred to our outpatient department.
We administered a digital rectal examination, and an
exophytic mass in the proximal anal canal was revealed.
Laboratory tests yielded significant results for the
following: CEA (43.75 ng/mL) and CA19-9 (11,790 unit/mL).
A computed tomography (CT) scan indicated segmental
wall thickening at the level of the rectum that was nearly
obstructing the bowel (Fig. 2A).
The results of the colonoscopy indicated a submucosal
rectal mass just above the dentate line (Fig. 2B). Multiple
biopsies were obtained from the mass during the colono-
scopy. The pathological examination indicated poorly
differentiated adenocarcinoma (Fig. 1). The microscopic
findings revealed pleomorphic tumor cells arranged in glan-
dular and solid nest patterns at the submucosa layer. The
immunohistochemical study demonstrated the expression of
CEA, positivity for cytokeratin 7 and cytokeratin 20, and
negativity for PSA and synaptophysin. A diagnosis of meta-
static poorly differentiated adenocarcinoma was rendered.
The aforementioned results led us to investigate the initial
bladder tumor specimens, which was confounded by a small
portion of the tumor that demonstrated high CEA expression
that was compatible with a diagnosis of a submucosal rectal
tumor. The patient was subsequently administered FOLFIRI
chemotherapy (folinic acid, fluorouracil, and irinotecan).
Three months later, after six cycles of chemotherapy,
repeated CT scans of the abdomen confirmed shrinkage of
the tumor. The results of the treatment were supported by
the laboratory data: 5.05 ng/mL CEA and 84.89 units/mL
CA19-9.
Discussion
Tumor heterogeneity can be characterized by differences
in histopathology and functional properties such asanchorage-independent growth, proliferative capacities,
and apoptotic responses to therapies [1]. Several studies
have suggested that such intraneoplastic heterogeneity
arises from genetic or epigenetic differences in tumor cells
via selective pressure that is exerted during tumor evolu-
tion. The identification of multiple components with
different histological patterns within a single malignant
tumor is a common finding in pathology. These variable
components are thought to result from tumor cell dedif-
ferentiation or transformation with the subsequent evolu-
tion of different subpopulations of tumor cells, a concept
that is illustrated by the coexistence of different carci-
nomas in the bladder. Several studies had reported that the
different components of urinary bladder carcinomas can
produce CEA or CA 19-9, as was true in our case [2e4].
CEA was first described by Gold and Freedman in 1965 [5]
as a complex glycoprotein on the cell surface that is
primarily produced during fetal development. It is overex-
pressed in several kinds of adenocarcinomas, including
those found in the colon, rectum, ovaries, and lung, and has
been widely used as a tool in diagnosis and disease follow-
up. CA 19-9 was discovered in patients with colon and-
pancreatic cancerin 1981 by Koprowski et al. [6]. It is
a tumor-associated antigen that is found in the cell
membrane, which has also been reported in association
with gastrointestinal carcinomas, thyroid papillary carci-
nomas, and endometrial adenocarcinomas. In general, CEA
and CA19-9 are well known tumor markers for a variety of
cancers of the digestive system. Although rare, they are
sometimes produced by urinary tract carcinomas [2e4]. In
our present case, high serum levels of CEA and CA19-9
initially led us to the diagnosis of newly developed rectal
tumor. Contiguous spread or metastasis from elsewhere
should always be clinically excluded, especially when the
patient has history of urothelial cell carcinoma. Diagnosing
poorly differentiated adenocarcinoma may be difficult or
impossible to distinguish from involvement by a primary
colon adenocarcinoma via histology [7]. The expression of
cytokeratin 7 has been reported in urothelial adenocarci-
noma, whereas the colonic epithelium and the majority of
colonic adenocarcinomas lack cytokeratin 7 immunoreac-
tivity [8]. In the present case, the rectal tumor was positive
for cytokeratin 7 and, therefore, considered to be a meta-
static tumor. Furthermore, on the colonoscopy findings, the
presence of a submucosal lesion also indicated that the
tumor came from the recurrent carcinoma. Our findings
show that the pelvic adenocarcinoma was immunohis-
tochemically similar to conventional urothelial cell
carcinoma.
It is widely accepted that heterogeneous cancers result
from the accumulation of mutations in the genes that
directly control cell birth and/or cell death. Such genetic
instabilities in tumor cells are partly induced by the tumor
environment, including cell-cell interactions, aberrant cell
substratum, and drug influence [9]. Usually gemcitabine
and cisplatin or MVAC (methotrexate, vinblastine, doxoru-
bicin, and cisplatin) serve as the first-line choice for
chemotherapy to treat urothelial cell carcinoma, whether
for neoadjuvant, adjuvant, or metastatic treatment. In this
case, paclitaxel, gemcitabine, and carboplatin were the
initial chemotherapeutic agents. After neoadjuvant
therapy, the tumor was downstaged to stage T0 following
Figure 1. Surgical specimen that was collected by transurethral resection of tumor. It is high-grade urothelial cell carcinoma of
bladder (A) that is positive for cytokeratin (CK) 7 (B), negative for CK 20 (C), and focally positive for CEA (D). The specimen was
collected during biopsy was diagnosed as a poorly differentiated adenocarcinoma (E) with CEA expression (H) that was positive for
CK 7 (F) and CK 20 (G).
626 M.-H. Yang et al.radical cystectomy. The symptoms of constipation
appeared 10 months later, allowing us to determine tumor
recurrence. The pathological report showed poorly differ-
entiated adenocarcinoma, which was sensitive to FOLFIRI
regimen therapy. Neoadjuvant chemotherapy mayselectively eliminate most urothelial cell carcinoma cells
but could still allow rectal metastasis through the actions of
any surviving CEA-producing components.
The treatment for these challenging cases often requires
a multidisciplinary approach and collaboration been
Figure 2. (A) CT scan showing segmental wall thickening at
the level of the rectum with a nearly obstructed bowel.
(B) Colonoscopy showing a submucosal rectal mass just above
the dentate line.
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that actively target both tumor components. Such an
approach would be useful if the disease burden of both
tumors is high and the patient’s condition does not permit
enough time to start definitive treatment to either
component. The disadvantage of this approach, however,
would be an inferior treatment outcome because this drug
combination is considered suboptimal for treating eitherurothelial cell carcinoma or adenocarcinoma. If the treat-
ment plan is aimed at one of the tumor components, it may
cause selective pressure that will result in the predomi-
nance of the other component.
This case emphasizes that clinicians need to keep in
mind the possibility of synchronous multiple tumor
components in patients with carcinomas. The importance
of recognizing this is due to its therapeutic and prognostic
implications, and recognizing this is will also prevent any
delays in the diagnosis of the coexisting tumor components.
In addition, awareness of this rare neoplasm can avoid
inaccurate staging and delays in the treatment of oncologic
patients with secondary tumor components. Understanding
the histological and clinical features of urothelial cell
carcinoma and the use of ancillary studies, such as immu-
nohistochemistry, should be considered to ensure proper
diagnosis and patient management.References
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